A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.

A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.